I meant that by excluding the sales volume of combination devices, for example, the total volume of hardware sales for 2026 would be 41 units. In 2027, 44 units, and in 2028, 55 units.
In this case, -5 to +12 devices from the realized figure would mean 36–53 devices in 2026. In 2027, 39–56 devices.
Where the actual trade volumes settle will be clarified in the future. And I am happy to update my own views as well.
Thanks @Blindfolded_Monkey for the ideas and help with styling the table. Readability has been improved, and CAGR calculations have been added to the relevant sections. That CAGR really illustrates well how, with fairly moderate sales growth, the bottom line grows at a nice pace.
That recurring revenue is a great productive and stabilizing component in Nexstim.
The styled table can be found at the same link: Nexstim - Arvaus tulevien vuosien kehityksestä - Google Sheets
Big thanks to Kyhnykeisari and colleague. Great table and sensible (not reaching for the moon) figures.
Sinaptica on LinkedIn;
Millions of people and families live with Alzheimer’s disease, losing precious memories and time together. The need for new treatment methods has never been greater.
At Sinaptica Therapeutics, we are developing a new type of therapy: non-invasive, precise #neuromodulation designed to target and restore the disrupted brain network responsible for memory, as well as to significantly improve patients’ lives.
This is science with a purpose. Technology built for scale. And a deep commitment to changing what is possible for people living with Alzheimer’s disease.
Watch and learn why we are building Sinaptica – and where we are headed next.
#DefaultModeNetwork (DMN) #MedTech #MedicalDeviceInnovation #InnovationInHealthcare #ENDALZ
Update: Now it’s already knocking on the $500 million mark. Nexstim’s fire sale continues and the market cap is still hovering around the 100 million mark.
The CEO talks about the journey toward profitability.
Can anyone give an estimate on how Nextim will take a hit if/when there’s a similar stock market crash this spring as there was a year ago?
I’ve been thinking about trimming my position just in case after the Q4 results.
I have only been actively getting to know investing for about a year. As I understand it, growth stocks react more, but on the other hand, Nextim is healthcare-related, which is defensive.
Thoughts?
I am not providing investment advice, but I encourage you to take a closer look at the company’s situation, particularly the sales development through Brainlab. There will likely be some update on that in the February results briefing. Personally, I value the company’s development, growth, and good management. Nexstim earns a plus in all these areas.
Focus on the company and its performance. Don’t worry about other “noise,” but these can certainly be used to add to your position.
I have personally looked into this a bit and have been actively following this forum for nearly two years. I have a decent understanding of the current situation. I do believe in Nextim’s operations and the stock’s good momentum over the next few years and beyond.
Regarding that question, I was mainly wondering how responsive the stock is to a potential market crash or a significant downturn where indices drop by around 20%. As I understand it, companies react differently to crashes, and I was hoping to get some thoughts on which “group” Nextim might belong to. Coca-Cola likely reacts differently than IREN, and NEXTIM differently than Nordea.
Well, I thought I’d care a little 
and at the same time learn how the global economy affects a small Finnish company. I believe that the better I understand things more broadly and the causal relationships between them, the better investment decisions I can make. So, I do have other holdings besides Nextim and will in the future as well.
I’m here on the forum to learn, and thanks for your perspective—I do understand that if you’ve invested in a company with the intention of holding for over 5 years, you don’t really need to worry about these index etc. drops as such. The most important thing is that the company survives through the downturn; the valuation will eventually correct back to a normal level over time.
These are the kind of companies where selling out completely, even for a moment, could be a mistake. With my luck, a takeover bid would come through right at that time, and that would be that. I’d probably rather trim my position if it feels that way. Wasn’t last year’s dip caused by these tariffs? I don’t really see that as a reason for another dip anymore. The reason would have to be something else.
My view is that Nexstim hardly suffers from the turmoil in the stock market. For example, the stock didn’t really care about the situation in Ukraine.
The number of devices sold is (still) counted in the dozens, and if someone wants a device, they will get it. Nexstim could thus be an even better safe haven than gold in the market turmoil, because it is able to continue its operations practically as normal, even if, for example, oil etc. were to become more expensive.
If you don’t want to be a paper hand, you should follow https://x.com/realroseceline.
If you have been part of a growth story from an early stage at a good price, it’s worth considering tax matters, especially the deemed acquisition cost (hankintameno-olettama).
There is no rush to make any decisions here. Things take time, and the Listeds piece linked by @Jatast is a good reminder of where we have come from, where we are, and where we are going.
Even if the company’s fundamentals don’t change, it is likely that Nexstim’s share price would also decline in the event of a broader market correction. Lower market risk tolerance = investors are willing to pay lower multiples for the stock (P/E, EV/EBIT, EV/S, etc.). Of course, the share price is also influenced by what kind of EPS the company managed to pull together for last year and how the story progresses in the future. If there is a steady stream of clearly positive news, a major dip might not necessarily occur if the fundamentals improve and sentiment remains positive.
The company is volatile.
I’ll share my views from a slightly different perspective than above, reflecting particularly on the impacts of the Sinaptica collaboration in the event of success or failure.
The stock price could be anything between €3 and €40 in the future. However, the company is at an interesting stage—especially for those whose purchase price is 5 or lower. A low purchase price changes the company’s profile from a high risk - high reward type of investment to a low risk - high reward one.
In my opinion, the company currently has a limited but tangible downside and potential for multi-fold upside. Why?
Failure:
If Sinaptica’s Phase 3 fails or commercialization remains minimal, the strategic cooperation on the diagnostic side with Brainlab is only just beginning, which supports the development of the diagnostics side. Depression treatment is also a developing market. Failure would have an impact on the company’s growth prospects and stock price, but in a limited way. The stock would likely find a new support level lower down. The shareholders’ purchase price is relevant here—whether the current profile is high risk - high reward or low risk - high reward.
Success:
Catalysts for growth:
Positive results from Sinaptica Phase 3
Phase 3 stage succeeds
Commercialization succeeds
It’s worth remembering that the treatment offered by Nexstim is not new in itself, but is an approved treatment method for depression, for example. My understanding is that the goal is to activate a specific brain region to aim for normalization of function. In other words, the method and mechanism are already familiar for activating different brain regions, but the area being treated is likely different, and consequently, the responses are too. This is what is currently being investigated.
Summary: There are many risks. There is both downside and upside to be found in the company. The geopolitical situation adds its own flavor. The company is, therefore, at least an interesting one to follow in the near future!
To clarify, that €40 is by no means an absolute maximum. If the company starts growing at a rapid pace and Alzheimer’s treatment with Nexstim’s device breaks through, it’s possible that the company’s value could rise even close to a billion. The share price would then be approx. €135 per share?
One must tolerate corrections; you should only invest as much as you are willing to lose. There are no stocks on the market immune to the storm.
You’re right. Forty is not an absolute maximum. However, a lot needs to happen. A better term would have been in the short or medium term.
Today on a run, I was thinking about the manufacturing of device components and the compositions of the raw materials used in them
I wonder if they contain metals whose availability could be affected or whose prices might rise significantly?
I’ll have to look into this at some point.
